Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
Filed with ASX · · 4 pages · English
SINGLE INTERVENTION WITH REXLEMESTROCEL-L IMPROVES LEFT VENTRICULAR EJECTION FRACTION AT 12 MONTHS, PRECEDING LONG-TERM REDUCTION IN MAJOR ADVERSE CARDIOVASCULAR EVENTS Key points: • Improvement in left ventricular ejection fraction (LVEF) at 12 months was shown after a single intervention with rexlemestrocel-L in the 565-patient randomized controlled trial in New York Heart Association (NYHA) cla
Earlier from Mesoblast
- Third Quarter Results Presentation
- MSB Q3 Financial Results and Operational Highlights
- S&P DJI Announces March 2022 Quarterly Rebalance
- Second Quarter Results Presentation
- Ulcerative Colitis & Crohns Results Presented at ECCO
Later from Mesoblast
- Reinstatement to Quotation
- US$45 Million Private Placement to Major Shareholders
- Preliminary Final Report
- MSB Annual Financial Results and Operational Highlights
- Submits New Information to FDA IND File for SR-aGVHD
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast